News Image

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Provided By GlobeNewswire

Last update: Apr 29, 2025

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day

Read more at globenewswire.com

NUVECTIS PHARMA INC

NASDAQ:NVCT (6/13/2025, 8:27:49 PM)

After market: 8.41 0 (0%)

8.41

-0.42 (-4.76%)



Find more stocks in the Stock Screener

Follow ChartMill for more